Enhanced chimeric antigen receptors and uses thereof

US11932690B2 · kind B2 · utility

Assignee

• Memorial Sloan Kettering Cancer Center · US

Inventors

• Michel Sadelain · New York, US
• Judith Feucht · Upfingen, DE
• Mohamad Hamieh · New York, US
• Jie Sun · San Diego, US
• Jorge Mansilla-Soto · Queens, US

Key dates

• Filing date: Jun 24, 2020
• Grant date: Mar 19, 2024
• Expiry date: Jul 24, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/10043
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of chimeric antigen receptors (CARs) and engineered immunoresponsive cells comprising the same. The engineered immunoresponsive cells comprising the novel CARs are antigen-directed and have extended persistence without compromising function.